Study on Relationship between of Fusion Gene and TCM Syndrome Classification in the Patient of Chronic Myelogenous Leukemia

Zhang Li; Wei Aihong; Wang Wei; et al.

doi:10.13288/j.11-2166/r.2006.04.032

您当前的位置：

首页 >

文章列表页 >

Study on Relationship between of Fusion Gene and TCM Syndrome Classification in the Patient of Chronic Myelogenous Leukemia

更新时间：2021-11-21

- Study on Relationship between of Fusion Gene and TCM Syndrome Classification in the Patient of Chronic Myelogenous Leukemia
- Journal of Traditional Chinese Medicine Issue 4, Pages: 293-294(2006)
- 作者机构：
  
  1. 中国人民解放军第二一医院中医血液病研究所
  2. 中国人民解放军沈阳军区卫生人员训练基地
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2006.04.032
  CLC： R273
- Published：2006
- 稿件说明：
移动端阅览
[1]张励,魏艾红,王伟,黄世林,杨英选,康洁霓.慢性粒细胞白血病融合基因与中医分型探讨[J].中医杂志,2006(04):293-294.

Zhang Li, Wei Aihong, Wang Wei, et al. Study on Relationship between of Fusion Gene and TCM Syndrome Classification in the Patient of Chronic Myelogenous Leukemia[J]. Journal of Traditional Chinese Medicine2006, (4): 293-294.
[1]张励,魏艾红,王伟,黄世林,杨英选,康洁霓.慢性粒细胞白血病融合基因与中医分型探讨[J].中医杂志,2006(04):293-294. DOI： 10.13288/j.11-2166/r.2006.04.032.

Zhang Li, Wei Aihong, Wang Wei, et al. Study on Relationship between of Fusion Gene and TCM Syndrome Classification in the Patient of Chronic Myelogenous Leukemia[J]. Journal of Traditional Chinese Medicine2006, (4): 293-294. DOI： 10.13288/j.11-2166/r.2006.04.032.

摘要

目的:探讨慢性粒细胞白血病（CML）患者BCR/ABL融合基因表达与中医辨证分型的关系。方法:采用筑巢式RT-PCR方法

扩增30例CML患者BCR/ABL融合基因

从分子生物学角度探讨其与中医分型的关系。结果:气阴两虚型与瘀血痰结型患者BCR/ABL基因阳性率明显高于毒热炽盛型（P<0.01）

经过治疗后

瘀血痰结型BCR/ABL基因阳性率高于气阴两虚型（P<0.05）。结论:90%以上的CML患者都具有BCR/ABL融合基因的表达

该融合基因是实验室诊断指标之一

其表达与变化为指导CML中医辨证诊治提供了客观指标。

Abstract

Objective:To study on relationship between of BCR/ABL fusion gene expression and TCM syndrome classification in the patient of chronic myelogenous leukemia（CML）.Methods:Nest-building RT-PCR method was used for amplification of BCR/ABL fusion gene in 30 cases of CML

so as to explore the relationship between gene and TCM syndrome classification from the perspective of molecular biology.Results:The positive rate of BCR/ABL gene in the patient with both qi and yin deficiency

and the patient of intermingled phlegm and blood stasis was significantly higher than that in the patient of intense noxious heat type（P<0.01）.After treatment

the positive rate of BCR/ABL gene in the patient of intermingled phlegm and blood stasis was higher than that in the patient with both qi and yin deficiency（P<0.05）.Conclusion:Over 90% patients of CML have expression of BCR/ABL fusion gene

which is a laboratory index for diagnosis of CML

and its expression and changes are an objective index for guiding diagnosis and treatment of CML.

关键词

Keywords

references

查看原文

Views

156

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese Medicine Syndrome Classification in 303 Elderly Patients with Pr imary Lung Cancer

Study on Relationship between TCM Syndrome Types of Gastric Carcinoma and Gastric Carcinoma Metastasis-Related Gene Ecadherin

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

Research on the Correlation Between "Tiangui （天癸）" and Female Reproductive Genetic Diseases

Syndrome Differentiation and Treatment of Cholinergic Urticaria from the Perspective of "Treating Fire Constraint by Dispersing It"

Related Author

YOU Jie

LI Taifeng

WANG Xia

Sun Dazhi Xu Ling He Jin

许玲

何金

魏品康

Related Institution

Longhua Hospital,Shanghai University of Chinese Medicine

Changzheng Hospital,Second Military Medical University

第二军医大学长征医院中医科、病理科上海市凤阳路415号

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰